Politecnico di Torino - Corso Duca degli Abruzzi, 24 - 10129 Torino, ITALY

+39 011 090 6100 info@tech-share.it

PROTEINS WITH CARDIOPROTECTIVE ACTIVITY

Biological drugsCardioprotectionCardioprotezioneCardiovascularheart failureMyocardial infarction

Introduction

The invention identifies three novel proteins exerting powerful cardioprotective activity on cardiac cells after Myocardial Infarction (MI). None of the three factors has been previously identified for activity in the cardiovascular system. The three factors can be developed as recombinant biological drugs to be administered to patients with myocardial infarction to protect the heart after MI and preserve cardiac function.

Technical features

Through an innovative method, based on AAV vector libraries, for the in vivo Functional Selection of bioactive proteins counteracting various degenerative conditions, including myocardial infarction, the screening aimed to identify novel factors to be used as biotherapeutics, in the absence of any a priori, possibly biased, information on their function. The in vivo screening of 1200 AAV coding for different genes, led to the identification of 3 factors with cardioprotective activity. These can be used as drugs, for example in the context of gene therapy or through the administration of recombinant or synthetic proteins, for the treatment or reduction of the risk of heart disease. In particular, the invention relates to the protection of the heart from the development of heart failure by preserving the vitality of the heart muscle cells. The conditions for which the drugs are effective include, for example, cardiac ischaemia (myocardial infarction and reperfusion injury), toxic cardiac injury and cardiomyopathy of genetic origin.

Possible Applications

  • Pharmaceutical sector;
  • Cardiovascular;
  • Cardioprotective treatment.

Advantages

  • New biological drug in a market that does not have new drugs since the 90s;
  • Biological drugs usually have physiological activity and are highly specific;
  • Factors subject of the invention can be transformed into injectable biological drugs, with no need to deliver their genes using viral vectors.